Descriptive Epidemiology on Management of Mucormycosis
Multicenter Observational Study on Epidemiology, Treatment and Outcome of Mucormycosis in India
1 other identifier
observational
500
1 country
13
Brief Summary
This is an observational chart review of all patients with confirmed and probable diagnosis of mucormycosis at 19 centers across Indian hospital. Data will collect using a standardized CRF. All collected data will be entered into a database prior to analysis. Broadly data will be collected on demography, clinical characteristics, diagnosis, treatment and outcome for each patient. Patient will continue to receive treatment as per treating physicians advise. Primary outcome for this study will be overall survival at 45 \& 90 days.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2016
13 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2016
CompletedFirst Submitted
Initial submission to the registry
July 29, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2017
CompletedFirst Posted
Study publicly available on registry
February 12, 2018
CompletedFebruary 12, 2018
February 1, 2018
1.5 years
July 29, 2017
February 8, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mortality
Number of deaths
Three months after the completion of the study
Eligibility Criteria
13 hospitals are identified across India for this study. All patients diagnose with confirmed and probable mucormycosis
You may qualify if:
- All consecutive patients regardless of age with a confirmed diagnosis mucormycosis through HPE \& /or culture will be enrolled in this study. In suspected cases on histopathology, molecular technique of extraction of DNA from tissue and sequencing to identify the pathogen, will be used to confirm the diagnosis
- All probable cases of mucormycosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fungal Infection Study Forumlead
- Mylan India Limitedcollaborator
Study Sites (13)
Sterling Hospital
Ahmedabad, Gujarat, 380052, India
St.Johns Medical College
Bangalore, Karnataka, 560034, India
PD Hinduja National Hospital and Medical Research centre
Mumbai, Maharashtra, 400016, India
All India Institute of Medical Sciences
New Delhi, National Capital Territory of Delhi, 110029, India
Sir Gangaram Hospital
New Delhi, National Capital Territory of Delhi, 110060, India
Indraprastha Apollo Hospitals
New Delhi, National Capital Territory of Delhi, 110076, India
VMMC and Safdarjung Hospital
New Delhi, National Capital Territory of Delhi, India
Christian Medical College and Hospital
Ludhiana, Punjab, 141008, India
Sri Ramachandra Medical College & RI
Chennai, Tamil Nadu, 600116, India
Christian Medical College
Vellore, Tamil Nadu, 632004, India
Nizams Institute Of Medical Sciences
Hyderabad, Telangana, 500082, India
PGIMER
Chandigarh, India
JIPMER
Puducherry, 605006, India
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chairman FISF
Study Record Dates
First Submitted
July 29, 2017
First Posted
February 12, 2018
Study Start
April 1, 2016
Primary Completion
September 30, 2017
Study Completion
September 30, 2017
Last Updated
February 12, 2018
Record last verified: 2018-02